CytRx Moves RNA Interference Into Separate Subsidiary
This article was originally published in The Pink Sheet Daily
Executive Summary
2006 Nobel Prize in Medicine recipient Craig Mello is a minority owner of RXi.
You may also be interested in...
CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition
Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.
CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition
Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.
Alnylam Seeks Deals As RNAi Interest Heats Up
Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.